A Resting Cell Assay for Improved Detection of Antibody-Mediated Neutralization of HIV Type 1 Primary Isolates

AIDS Research and Human Retroviruses

Volumn 11, Issue 12, 1995, Pages 1449-1458

  Zolla Pazner, Susan ^a   Sharpe, Sandra ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NORMAL HUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; HIV ANTIBODIES; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0029616489     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.1995.11.1449     Document Type: Article

References (51)

1. Dimmock MD: Neutralization of animal viruses. Curr Topics Microbiol Immunol 1993;183:1-149.
2. Sawyer LW, Wrin MT, Crawford-Miksza L, Potts B, We Y, Weber PA, Alfonso RD, and Hanson CV: Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994;68:1342-1349.
3. Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, and Burke DS: Two anti-genically distinct subtypes of HIV-1: Viral genotype predicts neutralization immunotype. J Infect Dis 1994;169:48-54.
4. D'Souza MP, Milman G, Bradac JA, McPhee D, Hanson CV, and Hendry RM: Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 1995;9:867-874.
5. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF III, and Burton DR: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gpl20, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.
6. Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Lasky LA, and Berman PW: Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (London) 1986;324:572-575.
7. Arendrup M, Sonnerborg A, Svennerholm B, Akerblom L, Nielsen C, Clausen H, Olofsson S, Nielsen JO, and Hansen JS: Neutralizing antibody response during human immunodeficiency virus type 1 infection: Type and group specificity and viral escape. J Gen Virol 1993;74:855-863.
8. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L, and Fenyo EM: Mother-to-child transmission of human immunodeficiency virus type 1: Correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993;168:207-210.
9. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, and Hanson CV: Neutralizing antibody responses to autologous and heterologous isolates of human inununodeficiency virus. J AIDS 1993;7:211-219.
10. Conley AJ, Gomy MK, Kessler JA II, Boots U, Lineberger D, Emini EA, Ossorio M, Koenig S, Williams C, and Zolla-Pazner S: Neutralization of primary HIV-1 virus isolates by the broadly-reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994;68:6994-7000.
11. Zolla-Pazner S, Gomy MK, Williams C. Burda S, and Sharpe S: Neutralization of HIV-1 primary isolates by human monoclonal antibodies. AIDS Res Hum Retroviruses 1994;10:sll 1.
12. Gomy MK, Xu J, Karwowska S, Buchbinder A, and Zolla-Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gpl20. J Immunol 1993; 150:635-643.
13. Daar ES, Li XL, Moudgil T, and Ho DD: High concentrations of recombinant soluble CD4 are required to neutralize primary HIV-1 isolates. Proc Natl Acad Sci USA 1990;87:6574-6578.
14. Gomy MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, and Zolla-Pazner S: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of HIV-1. J Virol 1994;68:8312-8320.
15. Golding H, D'Souza P, Bradac J, Mathieson B, and Fast P: The neutralization of HIV-1. AIDS Res Hum Retroviruses 1994; 10:633-643.
16. Baldinotti F, Matteucci D, Maxxetti P, Giannelli C, Bandecchi P, Tozzini F and Bendinelli M: Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the vims and host system. J Virol 1994;68:4572-4579.
17. Layne SP, Merges MJ, Cembo M, Spouge JL, Conley SR, Moore JP, Raina JL, Renz H, Gelderblom HR, and Nara PL: Factors underlying spontaneous inactivation and susceptibility to neutralization. Virology 1992;189:695-714.
18. Wawryk SO, Novotny JR, Wicks IP, Wilkinson D, Maher D, Salvaris E, Welch K, Fecondo J, and Boyd AW: The role of the LFA-l/ICAM-1 interaction in human leukocyte homing and adhesion. Immunol Rev 1989;108:135-161.
19. Bukrinsky MI, Stanwick TL, Dempsey MP, and Stevenson M: Quiescent T lymphocytes as an inducible vims reservoir in HIV-1 infection. Science 1991;254:423-427.
20. Stevenson M, Stanwick TL, Dempsey MP, and Lamonica CA: HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990;9:1551-1560.
21. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, and Chen ISY: HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral stmcture. Cell 1990;61: 213-222.
22. Zack JA, Haislip AM, Krogstad P, and Chen ISY: Incompletely reverse-transcribed human immunodeficiency vims type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992;66:1717-1725.
23. McDougal JS, Mawle A, Cort SP, Nicholson JKA, Cross GD, Scheppler-Campbell JA, Hicks D, and Sligh J: Cellular tropism of the human retrovims HTLV-III/LAV. J Immunol 1985;135:3151-3162.
24. Gomy MK, Xu J-Y, Gianakakos V, Karwowska S, Williams C, Sheppard HW, Hanson CV, and Zolla-Pazner S: Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the HIV-1 envelope glycoprotein. Proc Natl Acad Sci USA 1991;88:3238-3242.
25. Gomy MK, Conley AJ, Karwowska S, Buchbinder A, Xu J, Emini EA, Koenig S, and Zolla-Pazner S: Neutralization of diverse HIV-1 variants by an anti-V3 human monoclonal antibody. J Virol 1992;66:7538-7542.
26. Burke DS, Fowler AK, Redfield RR, Dilworth S, and Oster CN: Isolation of HIV-1 from the blood of seropositive adults: Patient stage of illness and sample inoculum size are major determinants of a positive culture. J AIDS 1990;3:1159-1167.
27. Zolla-Pazner S, O'Leary J, Burda S, Gomy MK, Kim M, Mascola J, and McCutchan F: Serotyping of primary human immunodeficiency vims type 1 isolates from diverse geographic locations by flow cytometry. J Virol 1995;69:3807-3815.
28. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, and Chen ISY: Dual infection of the central nervous system by AIDS vimses with distinct cellular tropisms. Science 1987;234:819-822.
29. Johnson VA and Byington RE: Infectivity assay (vims yield assay). In: Techniques in HIV Research (Aldovini A and Walker BD, eds.). Stockton Press, New York, 1990, pp. 71–76.
30. Laal S, Burda S, Sharpe S, and Zolla-Pazner S: A rapid, automated microtitre assay for measuring neutralization for HIV-1. AIDS Res Hum Retrovimses 1993;9:781-785.
31. Bollinger R.C. Jr, Kline R.L., Francis H.L., Moss M.W., Bartlett J.G., and Quinn T.C.: Acid dissociation increases the sensitivity of p24 antigen detection for the evaluation of antiviral therapy and disease progression in asymptomatic human immunodeficiency vims-infected persons. J Infect Dis 1992;165:913-916.
32. Zolla-Pazner S, Xu S, Sharpe S, and Giorgi J: Neutralizing activity in the sera of HIV-positive progressors and non-progressors. In preparation.
33. Buchbinder A, Karwowska S, Gomy MK, Burda ST, and Zolla-Pazner S: Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retrovimses 1992; 8:425-427.
34. Tilley SA, Honnen WJ, Racho ME, Chou T, and Pinter A: Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gpl20. AIDS Res Hum Retrovimses 1992;8:461-467.
35. Laal S, Burda S, Gomy MK, Karwowska S, Buchbinder A, and Zolla-Pazner S: Synergistic inhibition of HIV-1 replication by combinations of human monoclonal antibodies. J Virol 1993; 68:4001-4008.
36. Potts BJ, Field KG, Wu Y, Posner M, Cavacini L, and White-Scharf M: Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. Virology 1993;197:415-419.
37. Srivastava KK, Femandez-Larsson R, Zinkus DM, and Robinson HL: Human inmiunodeficiency vims type 1 NL4-3 replication in four T-cell lines: Rate and efficiency of entry, a major determinant of permissiveness. J Virol 1991,65:3900-3902.
38. Lu S, Putney SD, and Robinson HL: Human inununodeficiency vims type 1 entry into T cells: More rapid escape from an anti-V3 loop than from an antireceptor antibody. J Virol 1992;66:2547-2550.
39. Rivas A, Takada S, Koide J, Sounderstmp-McDevitt G, and Engelman EG: CD4 molecules re-associated with the antigen receptor complex on activated but not resting T cells. J Immunol 1988;140:2912-2918.
40. Franco L, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewica J, and Gallo RC: Hydroxyurea as an inhibitor of human immunodeficiency vims type-1 replication. Science 1994;266:801-805.
41. Gowda SD. Stein BS, Mohagheghpour N, Benike CJ, and Engleman EG: Evidence that T cell activation is required for HIV-1 entry in CD4-I- lymphocytes. J Immunol 1989;142:773-780.
42. Meerloo T, Sheikh MA, Bloem AC, de Ronde A, Schütten M, van Els CAC, Roholl PJM, Joling P, Goudsmit J, and Schuurman H: Host cell membrane proteins on human immunodeficiency vims type 1 after in vitro infection of H9 cells and blood mononuclear cells. An immuno-electron microscopic study. J Gen Virol 1993;74:129-135.
43. Capobianchi MR, Fais S, Castilletti C, Gentile M, Amelglio F, and Dianzani F: A simple and reliable method to detect cell membrane proteins on infectious human immunodeficiency virus type 1 particles. J Infect Dis 1994;169:886-889.
44. Berman PW and Nakamura GR: Adhesion mediated by intercellular adhesion molecule 1 attenuates the potency of antibodies that block HTV-1 gp 160-dependent syncytium formation. AIDS Res Hum Retroviruses 1994;10:585-593.
45. Gomez MP and Hildreth JEK: Antibody to adhesion molecule LFA-1 enhances AIDS plasma neutralization of HIV-1. J Virol 1995;69:4628-4632.
46. Arthur LO, Bess JW Jr, Sowder RC II, Benveniste RE, Mann DL, Chermann J-C, and Henderson LE: Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992;258:1935-1938.
47. Broder CC, Dimitrov DS, Blumenthal R, and Berger EA: The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal ceils expressing human CD4 can be overcome by a human cell component(s). Virology 1993;193:483-491.
48. Stefano KA, Collman R, Kolson D, Hoxie J, Nathanson N, and Gonzalez-Scarano F: Replication of a macrophage-tropic strain of human immunodeficiency virus type 1 (HTV-l) in a hybrid cell line, CEMxl74, suggests that cellular accessory molecules are required for HIV-1 entry. J Virol 1993;67:6707-6715.
49. Wrin R, Loh TP, Vennari JC, Schuitemaker H, and Nunberg JF: Adaptation to persistent growth in the H9 cell hne renders a primary isolate of human inmiunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995;69:39-48.
50. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, Williams C, and Chisholm P: Inhibition of HTV infection by a novel CD4 domain 2-specific monoclonal antibody. J Immunol 1992; 149:1779-1787.
51. Turner S, Tizard R, De Marinis J, Pepinsky RB, Zullo J, Schooley R, and Fisher R: Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gpl20. Proc Nati Acad Sci USA 1992;89:1335-1339.